NEW YORK (GenomeWeb) — Trovagene has entered into a strategic partnership with two Northwestern University institutions to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

Under the alliance, the Robert H. Lurie Comprehensive Care Center and the Northwestern Medicine Developmental Therapeutics Institute will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment, and assess their impact on overall disease management and patient outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.